Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 6/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CTRC | Q99895 | 2/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | EIF4E | P06730 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30947293 | 1.00 | AKR1B1 (0.47) | AKR1B1TBXAS1HSP90AA1LMNACTRC | |
| SCHEMBL30947332 | 0.90 | AKR1B1 (0.40) | AKR1B1CTRCNOS1METAP2 | |
| SCHEMBL22206466 | 0.90 | AKR1B1 (0.40) | AKR1B1CTRCNOS1METAP2 | |
| SCHEMBL21493503 | 0.75 | KDM4E (0.44) | L3MBTL1MEN1KMT2A | |
| SCHEMBL30693465 | 0.74 | AKR1B1 (0.49) | AKR1B1TBXAS1HSP90AA1LMNACTRC | |
| SCHEMBL21493437 | 0.74 | TSHR (0.32) | — | |
| SCHEMBL22206420 | 0.71 | PKM (0.44) | LMNAMEN1KMT2A | |
| SCHEMBL22206486 | 0.70 | CYP11B1 (0.47) | MEN1KMT2A | |
| SCHEMBL31095721 | 0.67 | HSP90AA1 (0.49) | AKR1B1HSP90AA1LMNACTSCL3MBTL1 | |
| SCHEMBL3741364 | 0.67 | HSP90AA1 (0.49) | AKR1B1HSP90AA1LMNACTSCL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| US-20240417392-A1 | 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2024-12-19 | — | — | US | disclosed |
| CN-113330001-B | 3, 3-Difluoroallylamine or salt thereof and pharmaceutical composition comprising the same | 柳韩洋行 | 2024-07-02 | — | — | CN | disclosed |
| CN-111886233-B | Triazolone derivatives or salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-01-02 | — | — | CN | disclosed |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-10-10 | — | — | US | disclosed |
| US-11713308-B2 | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-08-01 | — | — | US | disclosed |
| US-20230044255-A1 | 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2023-02-09 | — | — | US | disclosed |
| US-11168073-B2 | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2021-11-09 | — | — | US | disclosed |
| US-20210317110-A1 | TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2021-10-14 | — | — | US | disclosed |
| CN-113330001-A | 3, 3-difluoroallylamine or salt thereof and pharmaceutical composition containing same | 柳韩洋行 | 2021-08-31 | — | — | CN | disclosed |
| US-10995086-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2021-05-04 | — | — | US | disclosed |
| CN-111886233-A | Novel triazolone derivative or salt thereof and pharmaceutical composition comprising the same | 柳韩洋行 | 2020-11-03 | — | — | CN | disclosed |
| US-20200223827-A1 | 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2020-07-16 | — | — | US | disclosed |
| US-20190322655-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322655-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SLC10A1, VAPB, VAT1 | AKR1B1 456/4885TBXAS1 437/4885HSP90AA1 1977/4885 |
| US-11168073-B2 | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | VAPA, VAPB, SLC10A1 | AKR1B1 1292/4885TBXAS1 3455/4885HSP90AA1 2467/4885 |
| US-20210317110-A1 | TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SLC10A1, VAT1, LIPC | AKR1B1 499/4885TBXAS1 397/4885HSP90AA1 1669/4885 |
| US-20230044255-A1 | 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VAPA, VAPB, SLC10A1 | AKR1B1 1292/4885TBXAS1 3455/4885HSP90AA1 2467/4885 |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | SLC10A1, VAT1, LIPC | AKR1B1 499/4885TBXAS1 397/4885HSP90AA1 1669/4885 |
| US-20200223827-A1 | 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VAPA, VAPB, SLC10A1 | AKR1B1 1292/4885TBXAS1 3455/4885HSP90AA1 2467/4885 |
| US-20240417392-A1 | 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VAPA, VAPB, SLC10A1 | AKR1B1 1292/4885TBXAS1 3455/4885HSP90AA1 2467/4885 |
| US-11713308-B2 | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | VAPA, VAPB, SLC10A1 | AKR1B1 1292/4885TBXAS1 3455/4885HSP90AA1 2467/4885 |
| US-10995086-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | SLC10A1, VAT1, VAPB | AKR1B1 500/4885TBXAS1 419/4885HSP90AA1 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.